» Articles » PMID: 39913165

Senolytic Treatment Alleviates Corneal Allograft Rejection Through Upregulation of Angiotensin-Converting Enzyme 2 (ACE2)

Overview
Date 2025 Feb 6
PMID 39913165
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Allograft rejection remains a major cause of failure in high-risk corneal transplants, but the underlying mechanisms are not fully understood. This study aimed to investigate the contribution of transplantation stress-induced cellular senescence to corneal allograft rejection and to elucidate the associated molecular mechanisms.

Methods: Age-matched murine corneal transplantation models were established. Cellular senescence was evaluated using senescence-associated β-galactosidase (SA-β-Gal) staining, western blot, and immunofluorescence staining. The role of cellular senescence in corneal allograft rejection was analyzed using p16 knockout mice and adoptive transfer experiments. Senolytic treatment with ABT-263 was administered intraperitoneally to evaluate its effects on corneal allograft rejection. RNA sequencing and pharmacological approaches were employed to identify the underlying mechanisms.

Results: Surgical injury induced a senescence-like phenotype in both donor corneas and recipient corneal beds, characterized by an increased accumulation of SA-β-Gal-positive cells in the corneal endothelium and stroma and elevated expression of senescence markers p16 and p21. Using genetic and adoptive transfer models, transplantation stress-induced senescence was shown to exacerbate corneal allograft rejection. Importantly, clearance of senescent cells by ABT-263 significantly suppressed ocular alloresponses and immune rejection. Mechanistically, RNA sequencing and loss-of-function experiments demonstrated that the anti-rejection effects of senolytic treatment were closely dependent on angiotensin-converting enzyme 2 (ACE2).

Conclusions: These findings highlight transplantation stress-induced senescence as a pivotal pathogenic factor in corneal allograft rejection. Senolytic therapy emerges as a potential novel strategy to mitigate transplant rejection and improve corneal allograft survival.

References
1.
Scheuermann U, Zhu M, Song M, Yerxa J, Gao Q, Davis R . Damage-Associated Molecular Patterns Induce Inflammatory Injury During Machine Preservation of the Liver: Potential Targets to Enhance a Promising Technology. Liver Transpl. 2019; 25(4):610-626. PMC: 6593678. DOI: 10.1002/lt.25429. View

2.
Cantero-Navarro E, Fernandez-Fernandez B, Ramos A, Rayego-Mateos S, Rodrigues-Diez R, Sanchez-Nino M . Renin-angiotensin system and inflammation update. Mol Cell Endocrinol. 2021; 529:111254. DOI: 10.1016/j.mce.2021.111254. View

3.
Ferreira-Gonzalez S, Man T, Esser H, Aird R, Kilpatrick A, Rodrigo-Torres D . Senolytic treatment preserves biliary regenerative capacity lost through cellular senescence during cold storage. Sci Transl Med. 2022; 14(674):eabj4375. DOI: 10.1126/scitranslmed.abj4375. View

4.
Zhang W, Schonberg A, Hamdorf M, Georgiev T, Cursiefen C, Bock F . Preincubation of donor tissue with a VEGF cytokine trap promotes subsequent high-risk corneal transplant survival. Br J Ophthalmol. 2021; 106(11):1617-1626. DOI: 10.1136/bjophthalmol-2021-319745. View

5.
Chang J, Wang Y, Shao L, Laberge R, Demaria M, Campisi J . Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med. 2015; 22(1):78-83. PMC: 4762215. DOI: 10.1038/nm.4010. View